ASPiRA Labs Announces OVA1 Contract with Louisiana Blue Cross Blue Shield


 2017-10-31 VRML Contract w-Louisiana BCBS

AUSTIN, Texas, October 31, 2017 – ASPiRA Labs, a Vermillion company (NASDAQ: VRML) and exclusive distributor of OVA1 (Multivariate Index Assay, or MIA), an ovarian cancer risk assessment test, today announced it has entered into an agreement with Blue Cross Blue Shield of Louisiana.

“ASPiRA Labs has increased in-network coverage for OVA1 with BCBS of Louisiana,” said Fred Ferrara, Chief Operating Officer of Vermillion, Inc. “The expanded agreement, coupled with our existing coverage, now covers more than 82% of Louisiana’s population. As demonstrated in a series of recent announcements, we are making considerable strides in expanding access to OVA1, the strongest performing multi-algorithm ovarian cancer risk assessment test, to millions of women in 2017.”

Blue Cross Blue Shield of Louisiana provides approximately 1.45 million lives with in-network coverage throughout the state. This BCBS plan is in addition to existing TriCare, Medicare, and Medicaid plans that have OVA1 covered in Louisiana.

Expanding managed care access and demonstrating the impact of OVA1 to each healthcare plan is the foundation of ASPiRA Labs’ market adoption strategy. The evolution of payer relationships – from positive medical policy to in-network agreements – will be an ongoing theme going forward. More than 97 million lives are contracted or have a positive policy determination for OVA1.

OVA1 studies have demonstrated a reduction in false negative results, indicating earlier and improved detection of ovarian cancer compared to the standard of care. Detecting ovarian cancer at an early stage leads to improved patient outcomes while reducing costs to the healthcare system. Links to multiple clinical studies showing OVA1 (MIA)’s strong performance over CA125 and ROMA with ovarian cancer can be found on our website.

About Vermillion

Vermillion, Inc. is dedicated to the discovery, development and commercialization of novel high-value diagnostic and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women. Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases.  The company’s initial in vitro diagnostic test, OVA1® (MIA), was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016 Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. For additional information, including published clinical trials, visit

Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding Vermillion’s position to expand coverage for OVA1 (MIA). Words such as “may,” “expects,” “intends,” “anticipates,” “believes,” “estimates,” “plans,” “seeks,” “could,” “should,” “continue,” “will,” “potential,” “projects” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release are based on Vermillion’s expectations as of the date of this press release. A variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements, including changes to interpretations of existing laws and regulations and other factors that are described in Vermillion’s Form 10-K for the year ended December 31, 2016 and Form 10-Q for the quarter ended March 31, 2017 as filed with the Securities and Exchange Commission. Vermillion expressly disclaims any obligation to update, amend or clarify any forward-looking statements to reflect events, new information or circumstances occurring after the date of this press release, except as required by law.

Investor Relations Contact:

Michael Wood

LifeSci Advisors LLC

Tel 1-646-597-6983